LIFECORE BIOMEDICAL, INC. Comprehensive Income
LIFECORE BIOMEDICAL, INC. (LFCR) reported Comprehensive Income of $12.01 million for the 12-month period ending 2024-05-26, per its 10-K filed 2024-08-26.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2024-08-26
- LIFECORE BIOMEDICAL, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-05-26 was -$7.08M.
- LIFECORE BIOMEDICAL, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-02-25 was $15.63M.
- LIFECORE BIOMEDICAL, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-11-26 was $14.22M.
- LIFECORE BIOMEDICAL, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-08-27 was -$10.75M.
- LIFECORE BIOMEDICAL, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was $12.01M.
- LIFECORE BIOMEDICAL, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$98.98M.
- LIFECORE BIOMEDICAL, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$115.94M.
- LIFECORE BIOMEDICAL, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$30.84M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-05-26 | -$7.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-26 | $8.55M derived: sum of 2 quarters · filed 2024-08-26 | $22.77M derived: sum of 3 quarters · filed 2024-08-26 | $12.01M 10-K · filed 2024-08-26 | ||||
| 2024-02-25 | $15.63M 10-Q · filed 2024-08-09 | $29.85M derived: sum of 2 quarters · filed 2024-08-09 | $19.10M 10-Q · filed 2024-08-09 | -$20.19M derived: sum of 4 quarters · filed 2024-08-26 | ||||
| 2023-11-26 | $14.22M 10-Q · filed 2024-08-09 | $3.46M 10-Q · filed 2024-08-09 | -$35.82M derived: sum of 3 quarters · filed 2024-08-26 | -$72.33M derived: sum of 4 quarters · filed 2024-08-26 | ||||
| 2023-08-27 | -$10.75M 10-Q · filed 2024-08-09 | -$50.04M derived: sum of 2 quarters · filed 2024-08-26 | -$86.55M derived: sum of 3 quarters · filed 2024-08-26 | -$99.06M derived: sum of 4 quarters · filed 2024-08-26 | ||||
| 2023-05-28 | -$39.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-26 | -$75.79M derived: sum of 2 quarters · filed 2024-08-26 | -$88.31M derived: sum of 3 quarters · filed 2024-08-26 | -$98.98M 10-K · filed 2024-08-26 | ||||
| 2023-02-26 | -$36.51M 10-Q · filed 2024-08-09 | -$40.19M 10-Q · filed 2023-06-02 | -$49.03M derived: sum of 2 quarters · filed 2024-08-09 | -$59.69M 10-Q · filed 2024-08-09 | -$63.41M 10-Q · filed 2023-06-02 | -$114.84M derived: sum of 4 quarters · filed 2024-08-26 | ||
| 2022-11-27 | -$12.52M 10-Q · filed 2024-08-09 | -$12.16M 10-Q · filed 2023-03-16 | -$23.19M 10-Q · filed 2024-08-09 | -$23.21M 10-Q · filed 2023-03-16 | -$78.33M derived: sum of 3 quarters · filed 2024-08-26 | -$91.81M derived: sum of 4 quarters · filed 2024-08-26 | ||
| 2022-08-28 | -$10.67M 10-Q · filed 2024-08-09 | -$11.76M 10-Q · filed 2022-10-07 | -$65.81M derived: sum of 2 quarters · filed 2024-08-26 | -$79.29M derived: sum of 3 quarters · filed 2024-08-26 | -$117.59M derived: sum of 4 quarters · filed 2024-08-26 | |||
| 2022-05-29 | -$55.15M derived: 10-K 12 month − 10-K 9 month · filed 2024-08-26 | -$68.63M derived: sum of 2 quarters · filed 2024-08-26 | -$106.92M derived: sum of 3 quarters · filed 2024-08-26 | -$115.94M 10-K · filed 2024-08-26 | -$96.66M 10-K · filed 2022-09-14 | |||
| 2022-02-27 | -$13.48M 10-K · filed 2024-03-20 | -$12.75M 10-Q · filed 2022-04-07 | -$51.78M derived: sum of 2 quarters · filed 2024-03-20 | -$60.80M 10-K · filed 2024-03-20 | -$60.12M 10-Q · filed 2022-04-07 | -$61.72M derived: sum of 4 quarters · filed 2024-03-20 | ||
| 2021-11-28 | -$38.30M 10-K · filed 2024-03-20 | -$38.27M 10-Q · filed 2022-01-07 | -$47.32M 10-K · filed 2024-03-20 | -$47.38M 10-Q · filed 2022-01-07 | -$48.24M derived: sum of 3 quarters · filed 2024-03-20 | -$54.83M derived: sum of 4 quarters · filed 2024-03-20 | ||
| 2021-08-29 | -$9.02M 10-K · filed 2024-03-20 | -$9.11M 10-Q · filed 2021-10-05 | -$9.95M derived: sum of 2 quarters · filed 2024-03-20 | -$16.54M derived: sum of 3 quarters · filed 2024-03-20 | -$27.76M derived: sum of 4 quarters · filed 2024-03-20 | |||
| 2021-05-30 | -$925.00K derived: 10-K 12 month − 10-K 9 month · filed 2024-03-20 | -$7.52M derived: sum of 2 quarters · filed 2024-03-20 | -$18.74M derived: sum of 3 quarters · filed 2024-03-20 | -$30.84M 10-K · filed 2024-03-20 | -$31.21M 10-K · filed 2021-07-29 | |||
| 2021-02-28 | -$6.59M 10-K · filed 2024-03-20 | -$5.11M 10-Q · filed 2021-04-08 | -$17.81M derived: sum of 2 quarters · filed 2024-03-20 | -$29.92M 10-K · filed 2024-03-20 | -$28.71M 10-Q · filed 2021-04-08 | -$47.04M derived: sum of 4 quarters · filed 2024-03-20 | ||
| 2020-11-29 | -$11.22M 10-K · filed 2024-03-20 | -$12.90M 10-Q · filed 2021-01-07 | -$23.33M 10-K · filed 2024-03-20 | -$23.60M 10-Q · filed 2021-01-07 | -$40.45M derived: sum of 3 quarters · filed 2024-03-20 | -$52.38M derived: sum of 4 quarters · filed 2024-03-20 | ||
| 2020-08-30 | -$12.11M 10-K · filed 2024-03-20 | -$10.70M 10-Q · filed 2020-10-07 | -$29.23M derived: sum of 2 quarters · filed 2024-03-20 | -$41.16M derived: sum of 3 quarters · filed 2024-03-20 | -$47.77M derived: sum of 4 quarters · filed 2024-03-20 | |||
| 2020-05-31 | -$17.13M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-16 | -$29.05M derived: sum of 2 quarters · filed 2023-03-16 | -$35.67M derived: sum of 3 quarters · filed 2023-03-16 | -$41.06M 10-K/A · filed 2023-03-16 | ||||
| 2020-02-23 | -$11.93M 10-Q · filed 2021-04-08 | -$18.54M derived: sum of 2 quarters · filed 2021-04-08 | -$23.94M 10-Q · filed 2021-04-08 | -$24.68M derived: sum of 4 quarters · filed 2021-07-29 | ||||
| 2019-11-24 | -$6.61M 10-Q · filed 2021-01-07 | -$12.01M 10-Q · filed 2021-01-07 | -$12.75M derived: sum of 3 quarters · filed 2021-07-29 | -$12.27M derived: sum of 4 quarters · filed 2021-07-29 | ||||
| 2019-08-25 | -$5.40M 10-Q · filed 2020-10-07 | -$6.13M derived: sum of 2 quarters · filed 2021-07-29 | -$5.66M derived: sum of 3 quarters · filed 2021-07-29 | -$6.17M derived: sum of 4 quarters · filed 2021-07-29 | ||||
| 2019-05-26 | -$737.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-29 | -$265.00K derived: sum of 2 quarters · filed 2021-07-29 | -$773.00K derived: sum of 3 quarters · filed 2021-07-29 | -$673.00K 10-K · filed 2021-07-29 | ||||
| 2019-02-24 | $472.00K 10-Q · filed 2020-04-03 | -$36.00K derived: sum of 2 quarters · filed 2020-04-03 | $64.00K 10-Q · filed 2020-04-03 | |||||
| 2018-11-25 | -$508.00K 10-Q · filed 2020-01-02 | -$408.00K 10-Q · filed 2020-01-02 | ||||||
| 2018-05-27 | $25.55M 10-K · filed 2020-08-14 | |||||||
| 2017-02-26 | $3.60M 10-Q · filed 2017-04-07 | $5.26M derived: sum of 2 quarters · filed 2017-04-07 | $8.57M 10-Q · filed 2017-04-07 | $13.30M derived: sum of 4 quarters · filed 2017-04-07 | ||||
| 2016-11-27 | $1.65M 10-Q · filed 2017-01-05 | $4.96M 10-Q · filed 2017-01-05 | $9.69M derived: sum of 3 quarters · filed 2017-01-05 | -$11.50M derived: sum of 4 quarters · filed 2017-04-07 | ||||
| 2016-08-28 | $3.31M 10-Q · filed 2016-09-29 | $8.04M derived: sum of 2 quarters · filed 2016-09-29 | -$13.15M derived: sum of 3 quarters · filed 2017-04-07 | -$11.28M derived: sum of 4 quarters · filed 2017-04-07 | ||||
| 2016-05-29 | $4.73M 10-K · filed 2016-08-01 | -$16.46M derived: sum of 2 quarters · filed 2017-04-07 | -$14.59M derived: sum of 3 quarters · filed 2017-04-07 | -$11.64M 10-K · filed 2016-08-01 | ||||
| 2016-02-28 | -$21.19M 10-Q · filed 2017-04-07 | -$19.32M derived: sum of 2 quarters · filed 2017-04-07 | -$16.37M 10-Q · filed 2017-04-07 | -$12.17M derived: sum of 4 quarters · filed 2017-04-07 | ||||
| 2015-11-29 | $1.87M 10-Q · filed 2017-01-05 | $4.82M 10-Q · filed 2017-01-05 | $9.02M derived: sum of 3 quarters · filed 2017-01-05 | $12.79M derived: sum of 4 quarters · filed 2017-01-05 | ||||
| 2015-08-30 | $2.95M 10-Q · filed 2016-09-29 | $7.15M derived: sum of 2 quarters · filed 2016-09-29 | $10.92M derived: sum of 3 quarters · filed 2016-09-29 | $14.14M derived: sum of 4 quarters · filed 2016-09-29 | ||||
| 2015-05-31 | $4.20M 10-K · filed 2016-08-01 | $7.97M derived: sum of 2 quarters · filed 2016-08-01 | $11.19M derived: sum of 3 quarters · filed 2016-08-01 | $13.54M 10-K · filed 2016-08-01 | ||||
| 2015-03-01 | $3.77M 10-K · filed 2016-08-01 | $7.00M derived: sum of 2 quarters · filed 2016-08-01 | $9.35M 10-Q · filed 2016-03-30 | $13.89M derived: sum of 4 quarters · filed 2016-08-01 | ||||
| 2014-11-30 | $3.22M 10-K · filed 2016-08-01 | $5.58M 10-Q · filed 2016-01-07 | $10.12M derived: sum of 3 quarters · filed 2016-08-01 | $16.52M derived: sum of 4 quarters · filed 2016-08-01 | ||||
| 2014-08-31 | $2.35M 10-Q · filed 2015-10-01 | $6.89M derived: sum of 2 quarters · filed 2016-08-01 | $13.29M derived: sum of 3 quarters · filed 2016-08-01 | $16.75M derived: sum of 4 quarters · filed 2016-08-01 | ||||
| 2014-05-25 | $4.54M 10-K · filed 2016-08-01 | $10.94M derived: sum of 2 quarters · filed 2016-08-01 | $14.39M derived: sum of 3 quarters · filed 2016-08-01 | $19.14M 10-K · filed 2016-08-01 | ||||
| 2014-02-23 | $6.40M 10-K · filed 2016-08-01 | $9.85M derived: sum of 2 quarters · filed 2016-08-01 | $14.60M 10-Q · filed 2015-04-02 | $19.12M derived: sum of 4 quarters · filed 2016-08-01 | ||||
| 2013-11-24 | $3.45M 10-K · filed 2016-08-01 | $8.20M 10-Q · filed 2015-01-09 | $12.72M derived: sum of 3 quarters · filed 2016-08-01 | $17.51M derived: sum of 4 quarters · filed 2016-08-01 | ||||
| 2013-08-25 | $4.75M 10-K · filed 2016-08-01 | $9.27M derived: sum of 2 quarters · filed 2016-08-01 | $14.06M derived: sum of 3 quarters · filed 2016-08-01 | $22.97M derived: sum of 4 quarters · filed 2016-08-01 | ||||
| 2013-05-26 | $4.52M 10-K · filed 2015-07-31 | $9.31M derived: sum of 2 quarters · filed 2015-07-31 | $18.22M derived: sum of 3 quarters · filed 2015-07-31 | $22.59M 10-K · filed 2015-07-31 | ||||
| 2013-02-24 | $4.79M 10-K · filed 2015-07-31 | $13.70M derived: sum of 2 quarters · filed 2015-07-31 | $18.07M 10-Q · filed 2014-03-28 | $20.85M derived: sum of 4 quarters · filed 2015-07-31 | ||||
| 2012-11-25 | $8.91M 10-K · filed 2015-07-31 | $13.28M 10-Q · filed 2014-01-03 | $16.06M derived: sum of 3 quarters · filed 2015-07-31 | $20.82M derived: sum of 4 quarters · filed 2015-07-31 | ||||
| 2012-08-26 | $4.37M 10-K · filed 2015-07-31 | $2.54M 10-Q · filed 2012-10-03 | $7.14M derived: sum of 2 quarters · filed 2015-07-31 | $11.91M derived: sum of 3 quarters · filed 2015-07-31 | $15.25M derived: sum of 4 quarters · filed 2015-07-31 | |||
| 2012-05-27 | $2.78M 10-K · filed 2014-08-01 | $7.54M derived: sum of 2 quarters · filed 2014-08-01 | $10.88M derived: sum of 3 quarters · filed 2014-08-01 | $12.70M 10-K · filed 2014-08-01 | ||||
| 2012-02-26 | $4.76M 10-K · filed 2014-08-01 | $4.80M 10-Q · filed 2013-04-04 | $8.11M derived: sum of 2 quarters · filed 2014-08-01 | $9.98M 10-Q · filed 2013-04-04 | ||||
| 2011-11-27 | $3.34M 10-K · filed 2014-08-01 | $3.41M 10-Q · filed 2013-01-04 | $5.18M 10-Q · filed 2013-01-04 | |||||
| 2011-08-28 | $1.81M 10-K · filed 2014-08-01 | $1.78M 10-Q · filed 2012-10-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |